A study of functional and immunological outcomes in people undergoing robotic and non-robotic rectal cancer surgery

Not Applicable

• Conditions: Colorectal surgery for colorectal cancer; Surgery

• Registration Number: ISRCTN14199232
• Lead Sponsor: Portsmouth Hospitals NHS Trust

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-08-08
• Last Update Posted: 22 August 2022
• Study Completion: 2025-02-01

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

1. Age 18 years or above.
2. Diagnosed with rectal cancer, up to 15cm from the anal verge.
3. Local MDT recommends rectal cancer surgery (i.e. (high) anterior resection, partial TME, complete TME)
4. Patient assessed as fit for surgery (ASA I-III).
5. Patient willing and able to give informed consent for participation in the study.
6. Elective surgery.

Exclusion Criteria

1. Patient planned for Abdominoperineal Excision of Rectum (APER) or Hartmann’s procedure
2. Patients with confirmed or suspected metastatic disease.
3. Pregnant or breastfeeding patients.
4. Previous pelvic radiation for other cancers.
5. Inflammatory bowel disease (IBD).
6. Other known auto-immune disease which might influence the immune response (such as advanced liver disease, human immunodeficiency virus infection, Hepatitis B or C virus).
7. Use of anti-inflammatory medication (i.e. corticosteroids, anti-inflammatory drugs, immune modulating drugs, chronic use of antibiotics (the use of NSAIDS and steroid asthma inhalers will not be considered an exclusion criteria).
8. High pre-operative C-reactive protein (CRP) levels (>20).

Study & Design

• Study Type: Observational
• Study Design: Not specified